Details of the Drug

General Information of Drug (ID: DMM9BJD)

Drug Name
Tisagenlecleucel
Synonyms Tisagenlecleucel-T
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Diffuse large B-cell lymphoma 2A81 Phase 3 [2]
Follicular lymphoma 2A80 Phase 2 [2]
Acute myeloid leukaemia 2A60 Application submitted [3]
Drug Type
CAR T Cell Therapy
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 9.91 days [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 16.8 days [4]
Cross-matching ID
DrugBank ID
DB13881
TTD ID
D0IM6T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Immunostimulant [1]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Immunostimulant [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
10 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
11 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
12 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
13 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
14 Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.
15 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
16 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
18 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
19 Clinical pipeline report, company report or official report of Genentech (2009).
20 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
21 Clinical pipeline report, company report or official report of Roche (2009).
22 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
23 Clinical pipeline report, company report or official report of Genmab.